AbbVie releases positive top-line data from Phase III upadacitinib trial
Chicago, USA-based AbbVie (NYSE: ABBV) has announced positive top-line results from the Phase III SELECT-COMPARE trial of the JAK1 inhibitor upadacitinib in rheumatoid arthritis.
The trial met the primary endpoints of ACR20 and clinical remission, in comparison with placebo. All ranked secondary endpoints were also achieved versus either placebo or adalimumab.
The study showed that at week 12, 71% of patients receiving an oral once-daily dose of upadacitinib 15mg achieved an ACR20 response, compared with 36% of patients receiving placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze